Aktis Oncology (NASDAQ:AKTS) Earns Buy Rating from Analysts at TD Cowen

TD Cowen started coverage on shares of Aktis Oncology (NASDAQ:AKTS) in a research note released on Tuesday morning, Marketbeat Ratings reports. The brokerage issued a buy rating on the technology company’s stock.

Separately, Wall Street Zen raised Aktis Oncology to a “hold” rating in a report on Saturday, January 17th. Four analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $31.67.

Aktis Oncology Price Performance

Shares of NASDAQ:AKTS opened at $19.57 on Tuesday. Aktis Oncology has a 12-month low of $18.02 and a 12-month high of $29.16.

Insider Activity

In related news, major shareholder Bioventures 2018 L.P. Mpm acquired 1,112,777 shares of the company’s stock in a transaction on Monday, January 12th. The stock was purchased at an average cost of $18.00 per share, with a total value of $20,029,986.00. Following the acquisition, the insider directly owned 10,260,064 shares of the company’s stock, valued at approximately $184,681,152. The trade was a 12.17% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Helen Susan Kim bought 835,000 shares of the business’s stock in a transaction dated Monday, January 12th. The shares were bought at an average price of $18.00 per share, with a total value of $15,030,000.00. Following the completion of the transaction, the director owned 5,671,825 shares in the company, valued at approximately $102,092,850. This trade represents a 17.26% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have purchased 6,117,776 shares of company stock worth $110,119,968. 3.30% of the stock is currently owned by insiders.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.